Signalling cell cycle arrest and cell death through the MMR System

被引:167
作者
O'Brien, V [1 ]
Brown, R [1 ]
机构
[1] Canc Res UK Beatson Labs, Ctr Oncol & Appl Pharmacol, Glasgow G61 1BD, Lanark, Scotland
关键词
D O I
10.1093/carcin/bgi298
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Loss of DNA mismatch repair (MMR) in mammalian cells, as well as having a causative role in cancer, has been linked to resistance to certain DNA damaging agents including clinically important cytotoxic chemotherapeutics. MMR-deficient cells exhibit defects in G(2)/M cell cycle arrest and cell killing when treated with these agents. MMR-dependent cell cycle arrest occurs, at least for low doses of alkylating agents, only after the second S-phase following DNA alkylation, suggesting that two rounds of DNA replication are required to generate a checkpoint signal. These results point to an indirect role for MMR proteins in damage signalling where aberrant processing of mismatches leads to the generation of DNA structures (single-strand gaps and/or double-strand breaks) that provoke checkpoint activation and cell killing. Significantly, recent studies have revealed that the role of MMR proteins in mismatch repair can be uncoupled from the MMR-dependent damage responses. Thus, there is a threshold of expression of MSH2 or MLH1 required for proper checkpoint and cell-death signalling, even though sub-threshold levels are sufficient for fully functional MMR repair activity. Segregation is also revealed through the identification of mutations in MLH1 or MSH2 that provide alleles functional in MMR but not in DNA damage responses and mutations in MSH6 that compromise MMR but not in apoptotic responses to DNA damaging agents. These studies suggest a direct role for MMR proteins in recognizing and signalling DNA damage responses that is independent of the MMR catalytic repair process. How MMR-dependent G(2) arrest may link to cell death remains elusive and we speculate that it is perhaps the resolution of the MMR-dependent G(2) cell cycle arrest following DNA damage that is important in terms of cell survival.
引用
收藏
页码:682 / 692
页数:11
相关论文
共 147 条
[31]   INACTIVATION OF THE MOUSE MSH2 GENE RESULTS IN MISMATCH REPAIR DEFICIENCY, METHYLATION TOLERANCE, HYPERRECOMBINATION, AND PREDISPOSITION TO CANCER [J].
DEWIND, N ;
DEKKER, M ;
BERNS, A ;
RADMAN, M ;
RIELE, HT .
CELL, 1995, 82 (02) :321-330
[32]   ISOLATION OF AN HMSH2-P160 HETERODIMER THAT RESTORES DNA MISMATCH REPAIR TO TUMOR-CELLS [J].
DRUMMOND, JT ;
LI, GM ;
LONGLEY, MJ ;
MODRICH, P .
SCIENCE, 1995, 268 (5219) :1909-1912
[33]   Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line [J].
Drummond, JT ;
Anthoney, A ;
Brown, R ;
Modrich, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (33) :19645-19648
[34]   Human MutS alpha recognizes damaged DNA base pairs containing O-6-methylguanine, O-4-methylthymine, or the cisplatin-d(GpG) adduct [J].
Duckett, DR ;
Drummond, JT ;
Murchie, AIH ;
Reardon, JT ;
Sancar, A ;
Lilley, DM ;
Modrich, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (13) :6443-6447
[35]   Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes [J].
Durant, ST ;
Morris, MM ;
Illand, M ;
McKay, HJ ;
McCormick, C ;
Hirst, GL ;
Borts, RH ;
Brown, R .
CURRENT BIOLOGY, 1999, 9 (01) :51-54
[36]   ATR functions as a gene dosage-dependent tumor suppressor on a mismatch repair-deficient background [J].
Fang, Y ;
Tsao, CC ;
Goodman, BK ;
Furumai, R ;
Tirado, CA ;
Abraham, RT ;
Wang, XF .
EMBO JOURNAL, 2004, 23 (15) :3164-3174
[37]  
Fedier A, 2004, INT J ONCOL, V24, P1039
[38]  
Fink D, 1998, INT J CANCER, V77, P741, DOI 10.1002/(SICI)1097-0215(19980831)77:5<741::AID-IJC13>3.0.CO
[39]  
2-4
[40]  
Fink D, 1997, CANCER RES, V57, P1841